Urispas
Urispas Brand names, Urispas Analogs
Urispas Brand Names Mixture
- No information avaliable
Urispas Chemical_Formula
C58H73N7O17
Urispas RX_link
No information avaliable
Urispas fda sheet
Urispas msds (material safety sheet)
Urispas Synthesis Reference
No information avaliable
Urispas Molecular Weight
1140.24 g/mol
Urispas Melting Point
No information avaliable
Urispas H2O Solubility
Practically insoluble
Urispas State
Solid
Urispas LogP
0.216
Urispas Dosage Forms
Injection (50 mg vials to be reconstituted prior to injection)
Urispas Indication
For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.
Urispas Pharmacology
Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.
Urispas Absorption
No information avaliable
Urispas side effects and Toxicity
During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).
Urispas Patient Information
Urispas Organisms Affected
Aspergillis, Candida and other fungi
